Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Alberta Cancer Board Celgene Corporation Alberta Cancer Foundation |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00322985 |
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not well studied. Treatment approaches are patterned after the more common B-cell lymphomas. T-cell lymphomas are more likely to relapse following standard therapy than are B-cell lymphomas. New therapies are needed for T-cell lymphomas. In this study, we will administer the drug called lenalidomide as a pill to patients with T-cell lymphoma. The goals are to determine if the drug can induce regression of the cancer, and to determine if the treatment is well tolerated in this patient group. This study will take place at six cancer centres across Canada.
Condition | Intervention | Phase |
---|---|---|
T-Cell Lymphoma |
Drug: Lenalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Clinical Trial of Lenalidomide for T-Cell Non-Hodgkin's Lymphoma |
Estimated Enrollment: | 40 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tony Reiman, MD | 780-732-8513 | tonyreim@cancerboard.ab.ca |
Canada, Alberta | |
Cross Cancer Institute | Not yet recruiting |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Contact: Paula Langenhoff, BHA 780-432-8909 paulalan@cancerboard.ab.ca | |
Principal Investigator: Tony Reiman, MD | |
Cross Cancer Institute | Recruiting |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca |
Principal Investigator: | Tony Reiman, MD | Alberta Cancer Board |
Study ID Numbers: | HE-10-0090 |
Study First Received: | May 5, 2006 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00322985 |
Health Authority: | Canada: Health Canada |
T-cell lymphoma lenalidomide |
Lymphatic Diseases Immunoproliferative Disorders Lymphoma, T-Cell Lenalidomide |
Lymphoma, small cleaved-cell, diffuse Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |